[Low-dose oral contraception and bone density]

Area of Science:

• Endocrinology
• Bone Metabolism
• Reproductive Health

Context:

• Oral contraceptives (OC) containing 20 or 30 mcg Ethinyl-Estradiol (EE) are widely used for contraception.
• Concerns exist regarding the potential impact of low-dose EE on bone remodeling and peak bone mass, particularly in adolescents.
• Existing research indicates that these OCs inhibit bone remodeling biochemically across age groups.

Purpose:

• To evaluate the effect of low-dose oral contraceptives (OCs) containing Ethinyl-Estradiol (EE) on bone remodeling and bone density.
• To assess the potential impact on peak bone mass formation in young women.
• To explore alternative contraceptive methods for adolescents with potential skeletal health benefits.

Summary:

• Oral contraceptives (OCs) with 20 or 30 mcg Ethinyl-Estradiol (EE) inhibit bone remodeling biochemically.
• In perimenopausal women, these OCs reduce bone density loss and may increase bone density.
• Low-dose EE OCs might impede peak bone mass in women under 20 by reducing bone metabolism, though further studies are needed.
• Progestagen-only pills, like those with 30 mcg Levonorgestrel, may offer a viable alternative, maintaining estradiol levels sufficient for bone metabolism.

Impact:

• Low-dose EE OCs may pose a risk to skeletal health and peak bone mass development in adolescents.
• Further research is crucial to definitively assess the long-term skeletal effects of low-dose OCs in teenagers.
• Progestagen-only pills are suggested as a potentially safer contraceptive option for adolescents, supporting normal bone metabolism and peak bone mass.
• Adequate calcium, vitamin D, and physical activity are essential for achieving peak bone mass, independent of hormonal contraception.